Trial Profile

A Randomized, Phase 1b/2 Trial of Rilotumumab or Ganitumab in Combination With Panitumumab Versus Panitumumab Alone in Subjects With Wild-Type KRAS Metastatic Colorectal Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ganitumab (Primary) ; Rilotumumab (Primary) ; Panitumumab
Indications Adenocarcinoma; Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Amgen

Most Recent Events

21 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
22 Jan 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
28 Apr 2012 Planned number of patients changed from 132 to 153 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com